MethylGene Reports Favorable Phase I Data For MGCD265 In Solid Tumors At The AACR-NCI-EORTC International Conference
MethylGene Inc. (TSX:MYG) reported preliminary Phase I data for MGCD265 in a poster session at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston.
People who read this also read
- Large-Scale Study Reveals DNA Segments Missing Or Duplicated In Tumors, Uncovers Novel Cancer Genes And Genetic Abnormalities Shared Across Cancer
An international team of researchers has created a genome-scale map of 26 different cancers, revealing more than 100 genomic sites where DNA from tumors is either missing or abnormally duplicated comp... - Drug For Advanced Kidney Cancer Shrinks Tumors Prior To Surgery
More than 57,000 Americans face a diagnosis of kidney cancer each year. Now patients with advanced disease may soon have another treatment option. Physicians who conducted a pilot study at UNC Lineber... - Fluorescent Probes Light Up Cancerous Tumors
Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien,... - ERYtech Pharma Signs An Agreement With M. D. Anderson Cancer Center To Develop A Companion Test For GRASPA(R) In Solid Tumors
ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), is pleased to announce a collaborative research agreement in the field of personalized medicine focusing on ERYt... - Discovery Targets, Kills Tumors
A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancer... - Compugen Discovers Drug Target For Treatment Of Epithelial Tumors
Compugen Ltd. (NASDAQ: CGEN) announced the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors. CGEN-671 is a membrane splice variant of CD55, a known d... - Chicago Cancer Genome Project Studies Genetics Of 1,000 Tumors
No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention. That process is already gaining tract... - Fewer Left-Sided Colorectal Tumors Observed After Colonoscopies
The prevalence of left-sided advanced colorectal neoplasms was lower in participants in a community setting, but not right-sided advanced neoplams, who had received a colonoscopy in the preceding 10 y... - Chemo Side Effects Could Be Lessened By Nanoprobe-Targeting Of Tumors
Tiny nanoprobes have shown to be effective in delivering cancer drugs more directly to tumor cells - mitigating the damage to nearby healthy cells - and Purdue University research has shown that the n... - New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors In Women With Highly Advanced HER2-Positive Breast Cancer
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, ...


